Physician profile
Amber Delecce
NPI 1376258608
$1,245.89
in general payments reported to CMS, 2019-2025
9 companies · $542 in 2025
The $542 reported for 2025 was more than what 91% of Oncology (Registered Nurse) providers received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $704 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.95 |
| Education | $125.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $514.98 | 2024-2025 | Datroway, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $245.28 | 2024-2025 | Opdivo |
| Daiichi Sankyo INC. | $155.12 | 2024 | Enhertu, Injectafer |
| Incyte Corporation | $124.99 | 2025 | Zynyz |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Celgene Corporation | $35.04 | 2024 | |
| Pharmacosmos Therapeutics INC. | $30.28 | 2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $23.20 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Delecce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.